Skip to main content
main-content
Erschienen in: Current Urology Reports 1/2021

01.01.2021 | NEW IMAGING TECHNIQUES (S Rais-Bahrami and K Porter, Section Editors)

MR-Guided High-Intensity Directional Ultrasound Ablation of Prostate Cancer

verfasst von: Samuel J. Galgano, Virginia B. Planz, Sandeep Arora, Soroush Rais-Bahrami

Erschienen in: Current Urology Reports | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The goal of this paper was to review the novel treatment modality of high-intensity transurethral directional ultrasound for prostate cancer.

Recent Findings

Prostate cancer is a heterogeneous disease with some patients electing for active surveillance and focal therapies instead of definitive treatment with radical prostatectomy or radiation therapy. Prostate MRI has become a cornerstone of prostate cancer diagnosis, targeted biopsy, and treatment planning. Transurethral high-intensity directional ultrasound allows for MRI-guided ablation of the prostate gland with the ability to contour boundaries and spare critical structures, such as the neurovascular bundle and urinary sphincter. Although results are still emerging, this may offer patients a new option for focal therapy with a favorable side-effect profile.

Summary

High-intensity transurethral directional ultrasound is an emerging treatment modality for both whole-gland and focal ablation with promising early results. Further research is needed to establish safety, tolerability, and long-term oncologic outcomes.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. PubMed Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. PubMed
3.
Zurück zum Zitat Glaser ZA, Gordetsky JB, Bae S, Nix JW, Porter KK, Rais-Bahrami S. Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy. Urol Oncol. 2019;37(12):970–5. CrossRefPubMedPubMedCentral Glaser ZA, Gordetsky JB, Bae S, Nix JW, Porter KK, Rais-Bahrami S. Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy. Urol Oncol. 2019;37(12):970–5. CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90(10):766–71. CrossRefPubMed Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90(10):766–71. CrossRefPubMed
5.
Zurück zum Zitat Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52. PubMed Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52. PubMed
6.
Zurück zum Zitat Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–7. CrossRefPubMedPubMedCentral Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–7. CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–77. CrossRefPubMedPubMedCentral Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–77. CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Gordetsky JB, Saylor B, Bae S, Nix JW, Rais-Bahrami S. Prostate cancer management choices in patients undergoing multiparametric magnetic resonance imaging/ultrasound fusion biopsy compared to systematic biopsy. Urol Oncol. 2018;36(5):241 e7–e13. CrossRef Gordetsky JB, Saylor B, Bae S, Nix JW, Rais-Bahrami S. Prostate cancer management choices in patients undergoing multiparametric magnetic resonance imaging/ultrasound fusion biopsy compared to systematic biopsy. Urol Oncol. 2018;36(5):241 e7–e13. CrossRef
9.
Zurück zum Zitat Carroll PR, Presti JC Jr, Small E, Roach M 3rd. Focal therapy for prostate cancer 1996: maximizing outcome. Urology. 1997;49(3A Suppl):84–94. CrossRefPubMed Carroll PR, Presti JC Jr, Small E, Roach M 3rd. Focal therapy for prostate cancer 1996: maximizing outcome. Urology. 1997;49(3A Suppl):84–94. CrossRefPubMed
10.
Zurück zum Zitat Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Souchon R, et al. High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur Urol. 1993;23(Suppl 1):44–7. CrossRefPubMed Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Souchon R, et al. High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur Urol. 1993;23(Suppl 1):44–7. CrossRefPubMed
11.
Zurück zum Zitat Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 1995;55(15):3346–51. PubMed Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 1995;55(15):3346–51. PubMed
12.
Zurück zum Zitat Beerlage HP, van Leenders GJ, Oosterhof GO, Witjes JA, Ruijter ET, van de Kaa CA, et al. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate. 1999;39(1):41–6. CrossRefPubMed Beerlage HP, van Leenders GJ, Oosterhof GO, Witjes JA, Ruijter ET, van de Kaa CA, et al. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate. 1999;39(1):41–6. CrossRefPubMed
14.
Zurück zum Zitat Johnston MJ, Emara A, Noureldin M, Bott S, Hindley RG. Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-center in the United Kingdom. Urology. 2019;133:175–81. CrossRefPubMed Johnston MJ, Emara A, Noureldin M, Bott S, Hindley RG. Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-center in the United Kingdom. Urology. 2019;133:175–81. CrossRefPubMed
15.
Zurück zum Zitat Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540–5. CrossRefPubMed Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540–5. CrossRefPubMed
16.
Zurück zum Zitat Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74. CrossRefPubMed Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74. CrossRefPubMed
17.
Zurück zum Zitat Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, et al. Prostate specific antigen criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high intensity focused ultrasound. J Urol. 2020;203(4):734–42. CrossRefPubMed Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, et al. Prostate specific antigen criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high intensity focused ultrasound. J Urol. 2020;203(4):734–42. CrossRefPubMed
18.
Zurück zum Zitat Rosenhammer B, Niessen C, Rotzinger L, Reiss J, Schnabel MJ, Burger M, et al. Oncological outcome and value of postoperative magnetic resonance imaging after focal high-intensity focused ultrasound therapy for prostate cancer. Urol Int. 2019;103(3):270–8. CrossRefPubMed Rosenhammer B, Niessen C, Rotzinger L, Reiss J, Schnabel MJ, Burger M, et al. Oncological outcome and value of postoperative magnetic resonance imaging after focal high-intensity focused ultrasound therapy for prostate cancer. Urol Int. 2019;103(3):270–8. CrossRefPubMed
19.
Zurück zum Zitat Chopra R, Colquhoun A, Burtnyk M, N’Djin WA, Kobelevskiy I, Boyes A, et al. MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology. 2012;265(1):303–13. CrossRefPubMed Chopra R, Colquhoun A, Burtnyk M, N’Djin WA, Kobelevskiy I, Boyes A, et al. MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology. 2012;265(1):303–13. CrossRefPubMed
20••.
Zurück zum Zitat Chin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial. Eur Urol. 2016;70(3):447–55 Of major importance: Initial phase 1 trial of MRI-guided transurethral ablation of the prostate for prostate cancer. Chin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial. Eur Urol. 2016;70(3):447–55 Of major importance: Initial phase 1 trial of MRI-guided transurethral ablation of the prostate for prostate cancer.
21.
Zurück zum Zitat Ramsay E, Mougenot C, Staruch R, Boyes A, Kazem M, Bronskill M, et al. Evaluation of focal ablation of magnetic resonance imaging defined prostate cancer using magnetic resonance imaging controlled transurethral ultrasound therapy with prostatectomy as the reference standard. J Urol. 2017;197(1):255–61. CrossRefPubMed Ramsay E, Mougenot C, Staruch R, Boyes A, Kazem M, Bronskill M, et al. Evaluation of focal ablation of magnetic resonance imaging defined prostate cancer using magnetic resonance imaging controlled transurethral ultrasound therapy with prostatectomy as the reference standard. J Urol. 2017;197(1):255–61. CrossRefPubMed
22.
Zurück zum Zitat Bonekamp D, Wolf MB, Roethke MC, Pahernik S, Hadaschik BA, Hatiboglu G, et al. Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. Eur Radiol. 2019;29(1):299–308. CrossRefPubMed Bonekamp D, Wolf MB, Roethke MC, Pahernik S, Hadaschik BA, Hatiboglu G, et al. Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. Eur Radiol. 2019;29(1):299–308. CrossRefPubMed
24.
Zurück zum Zitat Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, et al. Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol. 2020;3:270–80. CrossRefPubMed Preisser F, Cooperberg MR, Crook J, Feng F, Graefen M, Karakiewicz PI, et al. Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol. 2020;3:270–80. CrossRefPubMed
25.
Zurück zum Zitat Scheltema MJ, Tay KJ, Postema AW, de Bruin DM, Feller J, Futterer JJ, et al. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol. 2017;35(5):695–701. CrossRefPubMed Scheltema MJ, Tay KJ, Postema AW, de Bruin DM, Feller J, Futterer JJ, et al. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol. 2017;35(5):695–701. CrossRefPubMed
26.
Zurück zum Zitat Thomsen FB, Roder MA, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, et al. Active surveillance versus radical prostatectomy in favorable-risk localized prostate cancer. Clin Genitourin Cancer. 2019;17(4):e814–e21. CrossRefPubMed Thomsen FB, Roder MA, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, et al. Active surveillance versus radical prostatectomy in favorable-risk localized prostate cancer. Clin Genitourin Cancer. 2019;17(4):e814–e21. CrossRefPubMed
27.
Zurück zum Zitat Ingrosso G, Becherini C, Lancia A, Caini S, Ost P, Francolini G, et al. Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3(2):183–97. CrossRefPubMed Ingrosso G, Becherini C, Lancia A, Caini S, Ost P, Francolini G, et al. Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3(2):183–97. CrossRefPubMed
28.
Zurück zum Zitat Marconi L, Stonier T, Tourinho-Barbosa R, Moore C, Ahmed HU, Cathelineau X, et al. Robot-assisted radical prostatectomy after focal therapy: oncological, functional outcomes and predictors of recurrence. Eur Urol. 2019;76(1):27–30. CrossRefPubMed Marconi L, Stonier T, Tourinho-Barbosa R, Moore C, Ahmed HU, Cathelineau X, et al. Robot-assisted radical prostatectomy after focal therapy: oncological, functional outcomes and predictors of recurrence. Eur Urol. 2019;76(1):27–30. CrossRefPubMed
30.
Zurück zum Zitat Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019;17(5):479–505. CrossRef Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2019;17(5):479–505. CrossRef
31.
Zurück zum Zitat Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199(3):683–90. CrossRefPubMed Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199(3):683–90. CrossRefPubMed
32.
Zurück zum Zitat Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, et al. Impact of (68)Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single center study. J Nucl Med. 2020;61:1153–60. CrossRefPubMedPubMedCentral Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, et al. Impact of (68)Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single center study. J Nucl Med. 2020;61:1153–60. CrossRefPubMedPubMedCentral
33.
34.
Zurück zum Zitat Hatiboglu G, Popeneciu V, Bonekamp D, Burtnyk M, Staruch R, Pahernik S, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters. World J Urol. 2020;38(2):343–50. CrossRefPubMed Hatiboglu G, Popeneciu V, Bonekamp D, Burtnyk M, Staruch R, Pahernik S, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters. World J Urol. 2020;38(2):343–50. CrossRefPubMed
35••.
Zurück zum Zitat Sundaram KM, Staruch R, Burtnyk M, Lane JS, Penson DF, Arora SS. MR imaging-guided transurethral ultrasound ablation of localized prostate cancer: preliminary experience from a single center in a prospective, multi-center, single-arm clinical trial. J Vasc Interv Radiol. 2020;31(5):740–6 e4 Of major importance: Initial published data from the phase 2 trial of TULSA for MRI-guided transurethral ultrasound ablation of prostate cancer. CrossRefPubMed Sundaram KM, Staruch R, Burtnyk M, Lane JS, Penson DF, Arora SS. MR imaging-guided transurethral ultrasound ablation of localized prostate cancer: preliminary experience from a single center in a prospective, multi-center, single-arm clinical trial. J Vasc Interv Radiol. 2020;31(5):740–6 e4 Of major importance: Initial published data from the phase 2 trial of TULSA for MRI-guided transurethral ultrasound ablation of prostate cancer. CrossRefPubMed
Metadaten
Titel
MR-Guided High-Intensity Directional Ultrasound Ablation of Prostate Cancer
verfasst von
Samuel J. Galgano
Virginia B. Planz
Sandeep Arora
Soroush Rais-Bahrami
Publikationsdatum
01.01.2021
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 1/2021
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-020-01020-y

Weitere Artikel der Ausgabe 1/2021

Current Urology Reports 1/2021 Zur Ausgabe

Benign Prostatic Hyperplasia (K McVary, Section Editor)

What Is New with Rezūm Water Vapor Thermal Therapy for LUTS/BPH?

NEW IMAGING TECHNIQUES (S Rais-Bahrami and K Porter, Section Editors)

Dual-Energy CT for Urinary Stone Evaluation

NEW IMAGING TECHNIQUES (S Rais-Bahrami and K Porter, Section Editors)

From Diagnosis to Therapy—PET Imaging for Pheochromocytomas and Paragangliomas

Neu im Fachgebiet Urologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Urologie und bleiben Sie gut informiert – ganz bequem per eMail.